Kumud Kalia

Guardant Health CIO Kumud Kalia sold 5,000 shares at $130.41 on 2026-06-10 for $652,030.00

Kumud Kalia, Chief Information Officer, sold 5,000 shares at $130.41, reducing holdings from 49.5K to 44.5K shares (-10.1%). The stock is currently at $131.62, up +33.7% over 30 days and +54.0% over 90 days. Kalia's prior trades at GH show a mixed timing pattern: two prior sales on 2026-03-04 resulted in 90-day returns of +36.8% and +36.0% respectively, both occurring after the insider sold. His cross-ticker selling history shows an average 90-day return of +36.4% with a 0.00% well-timed rate, indicating prior sales preceded stock appreciation. The company generated $301.7M in quarterly revenue with +32.9% annual growth but remains unprofitable with full-year net income of -$112.1M, presenting a growth story offset by ongoing losses.

Guardant Health CIO sells 40,000 shares ($3.8M) in two transactions; 51.5% stake reduction near 52-week highs

Kalia Kumud, Chief Information Officer, executed two separate open-market sales on 2026-03-04, selling 26,980 shares at $95.12 and 13,020 shares at $95.73, totaling 40,000 shares (40.0K shares) for $3,812,660.54 at a blended average price of $95.32. This represents a 51.5% reduction in his post-transaction holdings from 77,643 shares to 37,643 shares. The transaction prices of $95.12 and $95.73 occurred near the 52-week high of $117.28 (stock has since declined 21.1% from that peak). His prior trades at Guardant Health show a 90-day win rate of 100% with gains of +69.6%, +8.0%, and +7.6%, indicating historically well-timed entry decisions, though this sell-timing framework differs from buy-timing. The company reported a net loss of $92,725,000.00 over its most recent full fiscal year while generating $265,196,000.00 in quarterly revenue with 32.9% annual growth, contextualizing this large equity position reduction against an unprofitable business in a growth phase.